

Lipoprotein Lipase Is a Gene for Insulin Resistance in Mexican Americans

Mark O. Goodarzi,^{1,2} Xiuqing Guo,¹ Kent D. Taylor,¹ Manuel J. Quiñones,² Mohammad F. Saad,³ Huiying Yang,¹ Willa A. Hsueh,² and Jerome I. Rotter¹

The insulin resistance syndrome is increasingly recognized as a risk factor for cardiovascular disease. Lipoprotein lipase (*LPL*) is a candidate gene for components of the syndrome. A small number of studies have demonstrated association of single nucleotide polymorphisms within *LPL* and indirect or surrogate measures of insulin resistance, largely based on glucose and insulin values obtained in the fasting state or during an oral glucose tolerance test. To test directly whether *LPL* is an insulin resistance gene, we performed the hyperinsulinemic-euglycemic clamp in a large family-based population of Mexican Americans who were genotyped at six polymorphisms in *LPL* that define the most common haplotypes in the population. *LPL* haplotypes showed linkage to the glucose infusion rate (GINF), a direct physiologic measurement of insulin sensitivity ($P = 0.034$). In addition, significant associations with GINF were demonstrated for the most common haplotype ($P = 0.031$) and the fourth most common haplotype ($P = 0.007$). Haplotype 1 was associated with insulin sensitivity (mean GINF for haplotype 1 carriers = 383.0 mg/min) and haplotype 4 with insulin resistance (mean GINF for haplotype 4 carriers = 344.3 mg/min). This haplotype-based genetic analysis provides compelling evidence that variation in the *LPL* gene plays a role in determining insulin resistance in this ethnic group with a high prevalence of the insulin resistance syndrome. *Diabetes* 53:214–220, 2004

The insulin resistance syndrome (also called the metabolic syndrome) is a clustering of factors associated with an increased risk of coronary heart disease (CHD) (1). The syndrome affects >20% of adults in the U.S., with the highest age-specific prevalence rates in Mexican Americans (2). Insulin resistance, whether accompanied by other features of the

metabolic syndrome, has been associated with an increased risk of cardiovascular events and death (3,4). Given the association of insulin resistance and CHD, attention has been turned to identifying genetic determinants underlying the insulin resistance syndrome.

The lipoprotein lipase (*LPL*) gene has emerged as a candidate gene for features of the metabolic syndrome. Studies have identified linkage and association of the *LPL* gene with hypertension (5,6), indirect or surrogate measurements of insulin resistance (7,8), dyslipidemia (7,9–11), obesity (11), and atherosclerosis (12–14). *LPL* is an excellent candidate connecting insulin resistance to atherosclerosis because it controls the delivery of free fatty acids (FFAs) to muscle, adipose tissue, and vascular wall macrophages, wherein lipid uptake influences peripheral insulin sensitivity, central obesity, and foam cell formation (15).

We have genotyped a series of *LPL* 3' end single nucleotide polymorphisms (SNPs) to determine the haplotype structure of this region of the *LPL* gene in the Mexican-American population. Our efforts are focused on the 3' end of the *LPL* gene because polymorphisms in the 3' end, such as *Hind*III, have been associated with surrogate measures of insulin resistance and atherosclerosis (7,8,13,14). To date, each of several published reports of positive linkage or association of variation in *LPL* with indexes of insulin sensitivity examined only one or two SNPs (7,8,16–21). Recent studies suggest that the extensive variation in human beings is best described by groups of associated polymorphisms referred to as haplotypes (22,23). Haplotypes encompass chromosomal blocks that have remained unbroken by recombination during the population evolutionary history of the gene. Haplotypes are more likely to identify disease associations than single polymorphisms because they reflect global gene structure and encompass the majority of common variation in a gene. Identification of a haplotype associated with increased or decreased disease risk should facilitate identification of the actual functional variant that affects disease risk because this variant should lie on chromosome regions identified by that haplotype (24). Using a haplotype-based analysis, we recently demonstrated association of *LPL* 3' end haplotypes with coronary artery disease (CAD) in Mexican Americans (14). Our goal herein was to use these haplotypes to explore association of variation in *LPL* with insulin resistance.

Besides examining only one variant in the *LPL* gene, prior studies suggesting that *LPL* influences insulin sensitivity often used only surrogate measurements of insulin

From the ¹Division of Medical Genetics, Departments of Pediatrics and Medicine, Steven Spielberg Pediatric Research Center, Cedars-Sinai Medical Center, Los Angeles, California; the ²Division of Endocrinology, Diabetes, and Hypertension, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California; and the ³Division of Epidemiology and Preventive Medicine, Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California.

Address correspondence and reprint requests to Mark O. Goodarzi, MD, Cedars-Sinai Medical Center, Division of Medical Genetics, 8700 Beverly Blvd., SSB 378, Los Angeles, CA 90048. E-mail: mgoodarzi@mednet.ucla.edu.

Received for publication 11 June 2003 and accepted in revised form 3 October 2003.

CAD, coronary artery disease; CHD, coronary heart disease; FFA, free fatty acid; GINF, glucose infusion rate; HOMA, homeostasis model assessment; *LPL*, lipoprotein lipase; MACAD, Mexican-American Coronary Artery Disease; SNP, single nucleotide polymorphism.

© 2004 by the American Diabetes Association.

TABLE 1
LPL single marker and haplotype frequencies in Mexican Americans

SNPs and major allele frequencies	7315 G→C 0.89	8292 A→C 0.85	8393 T→G 0.80	8852 T→G 0.78	9040 C→G 0.93	9712 G→A 0.88	Chromosomes	Frequency (%)
Haplotype 1	G	A	T	T	C	G	206	62.8
Haplotype 2	G	C	T	T	C	G	50	15.2
Haplotype 3	C	A	G	G	C	A	33	10.1
Haplotype 4	G	A	G	G	G	G	22	6.7
Haplotype 5	G	A	G	G	C	A	8	2.4
Haplotype 6	G	A	T	G	C	G	6	1.8
Haplotype 7	C	A	G	G	C	G	2	0.5
Haplotype 8	G	A	G	G	C	G	1	0.3

sensitivity, typically based on blood taken in the fasting state or during an oral glucose tolerance test (7,16–21). Thus, current evidence that variation in *LPL* plays a role in insulin sensitivity is indirect. Assessment of the glucose infusion rate (GINF) during the hyperinsulinemic-euglycemic clamp study is widely regarded as the most direct physiologic measurement of insulin sensitivity (25). To address this issue directly, in this study we assessed insulin sensitivity by the euglycemic clamp as the phenotype for linkage and association. In addition, we used haplotypes rather than a SNP. Our results provide direct evidence that *LPL* is an insulin resistance gene by demonstration of both linkage and association of *LPL* haplotypes with a direct quantitative measurement of insulin resistance in Mexican-American families.

RESEARCH DESIGN AND METHODS

The UCLA/Cedars-Sinai Mexican-American Coronary Artery Disease (MACAD) project enrolls families ascertained through a proband with CAD, determined by evidence of myocardial infarction on electrocardiogram or hospital record, evidence of atherosclerosis on coronary angiography, or history of coronary artery bypass graft or angioplasty (14). Two generations are enrolled in the study: 1) the proband and proband spouses (parental generation); and 2) their adult (aged ≥ 18 years) offspring and the spouses of those offspring (offspring generation). DNA was obtained for genotyping from members of both generations, and only members of the offspring generation were asked to undergo a series of tests to characterize their metabolic and cardiovascular phenotype.

All studies were approved by Human Subjects Protection Institutional Review Boards at UCLA and Cedars-Sinai Medical Center. All subjects gave informed consent before participation.

Genotyping. In a prior study, we determined a set of six SNPs that are sufficient to identify the most common haplotypes occurring in the 3' end of the *LPL* gene (14). These are 7315, 8292, 8393, 8852, 9040, and 9712. The numbering of the SNPs corresponds to Genbank accession no. AF050163, which describes a 9.7-kb segment of the *LPL* gene originally sequenced in the MDECODE (Molecular Diversity and Epidemiology of Common Disease) project, a study of Finns, non-Hispanic Caucasian Americans, and African-American subjects (26). SNP 8393 is the *Hind*III variant located in intron 8, and 9040 is the Ser447Stop variant located in exon 9. SNP 7315 is in intron 7, 8292 and 8852 are in intron 8, and 9712 is in intron 9. Large-scale genotyping of the six SNPs in MACAD families was performed using the 5'-exonuclease (Taqman MGB) assay (27). A description of this technique and PCR primer and oligonucleotide probe sequences is given in Goodarzi et al. (14).

LPL markers were genotyped in 514 individuals from 85 MACAD families. Of these, 29 genotyped individuals were discarded because their genotypes were incompatible with their family pedigree, as detected by the program PedCheck (28). This left 485 individuals from 80 families genotyped at *LPL*. The genotype frequencies for all six markers were in Hardy-Weinberg equilibrium. Linkage disequilibrium among the six markers (D') ranged from 0.46 to 0.87 (29).

Phenotyping. The adult offspring of the proband and the spouses of the offspring undergo a 3-day phenotyping protocol, which includes indexes of insulin resistance determined by euglycemic clamp. Of the 485 subjects genotyped at *LPL*, 125 were from the parental/proband generation that was

not phenotyped, and 69 (from six families) from the offspring generation were not clamped. Thus, 291 subjects from 74 families were both clamped and genotyped for the *LPL* markers.

Several indexes of insulin sensitivity are obtained in the MACAD study. Fasting insulin and glucose, themselves simple surrogate measures of insulin sensitivity, allow calculation of the homeostasis model assessment (HOMA) index. Using glucose in mmol/l and insulin in $\mu\text{IU/ml}$, the HOMA index is calculated as $(\text{glucose} \times \text{insulin})/22.5$. An ideal, normal-weight person aged <35 years has a HOMA of 1 (30).

During the hyperinsulinemic-euglycemic clamp (25), a priming dose of human insulin (Novolin; Novo Nordisk, Clayton, NC) was given and followed by infusion for 120 min at a constant rate ($60 \text{ mU} \cdot \text{m}^{-2} \cdot \text{min}^{-1}$) to achieve a plasma insulin concentration of $\geq 100 \mu\text{IU/ml}$. Blood was sampled every 5 min, and the rate of 20% dextrose coinfusion was adjusted to maintain plasma glucose concentrations at 95–100 mg/dl. The GINF (given in mg/min) over the last 30 min of steady-state insulin and glucose concentrations reflects glucose uptake by all tissues of the body (primarily insulin-mediated glucose uptake in muscle) and is therefore a direct physiologic measurement of tissue insulin sensitivity. GINF is also often reported divided by body weight, resulting in a trait termed the M value ($\text{mg} \cdot \text{kg}^{-1} \cdot \text{min}^{-1}$) (25). GINF and the M value underestimate the total glucose disposal rate during the euglycemic clamp in conditions where hepatic glucose output is not completely suppressed by the insulin infusion. In nondiabetic insulin-resistant subjects, such as those in our study, M underestimates total glucose disposal only by $\leq 10\%$ (31).

Data analysis. Based on the pedigree structures and genotype data of all individuals in each pedigree, haplotypes were constructed as the most likely set (determined by the maximum likelihood method) of fully determined parental haplotypes of the marker loci for each individual in the pedigree, using the simulated annealing algorithm implemented in the program Simwalk2 (32). Using this method, we were able to assign haplotypes to 475 of the 485 genotyped subjects, including 284 of the 291 genotyped and clamped subjects, comprising 199 offspring and 85 offspring spouses. Founder haplotypes, i.e., those haplotypes from parents (48 spouses of probands) and individuals marrying into the families (116 spouses of offspring), were used to calculate haplotype frequencies in 328 chromosomes from 164 Mexican-American founders without CAD. The frequencies of the most common haplotypes are displayed in Table 1 along with the major allele frequencies of the six SNPs. The markers from Mexican Americans without CAD were used for haplotype frequency estimation in order to eliminate any disease-based ascertainment bias.

Log-transformed (anthropometric measurements, fasting glucose, and fasting insulin) or square root-transformed (HOMA, GINF, and M) trait values were used to reduce skewness for all statistical analyses. Unpaired, two-sided t tests were used to compare trait values between men and women.

Linkage was assessed using sibpair analysis (33). The basic idea of this approach is that if a locus influences the quantitative trait or phenotype under study, then siblings who share more alleles at that locus will be more similar in phenotype than siblings who share fewer alleles. Conceptually, this procedure first plots the square of the difference in the quantitative trait between each sibpair versus the number of alleles shared and then uses linear regression to estimate how much of the difference in the trait depends on the number of alleles shared. A significant linkage is shown by a negative regression coefficient. If there is no linkage, the regression coefficient is expected to be zero. We used the SIBPAL2 program in SAGE 4.2 (34) to implement a sibpair analysis that uses the mean-corrected cross-product instead of the squared difference of the sibs' trait values as the dependent variable; this revised method has more power and accommodates multiple sibs in a family (35). Age, sex, and BMI were specified as covariates in the

TABLE 2
Clinical characteristics of 291 genotyped and clamped individuals

	Men	Women
<i>n</i>	112	179
Age (years)	35 ± 9.4 (19–60)	35.5 ± 8.2 (18–58)
Weight (kg)*	84.2 ± 15.6 (52.5–126.6)	72.1 ± 14.0 (38.6–128.5)
Body mass index (kg/m ²)	28.9 ± 4.8 (17.8–45.4)	29.1 ± 5.5 (18.1–54.8)
Fasting glucose (mg/dl)†	96.1 ± 9.8 (74.0–118.0)	92.5 ± 9.4 (56.0–117.0)
Fasting insulin (μIU/ml)	15.4 ± 8.9 (5.0–62.0)	15.5 ± 7.5 (2.0–49.0)
HOMA	3.7 ± 2.4 (1.2–15.9)	3.6 ± 1.9 (0.5–14.0)
GINF (mg/min)‡	428.6 ± 196.8 (105.9–1031.5)	343.5 ± 147.5 (20.7–1010.5)
<i>M</i> (mg · kg ⁻¹ · min ⁻¹)	5.4 ± 2.8 (1.0–13.9)	5.0 ± 2.4 (0.2–14.9)

Data are mean ± SD (range). Comparing men versus women, **P* < 0.00001, †*P* = 0.005, ‡*P* = 0.0001.

linkage analysis. Among our subjects who were genotyped and clamped, we had available 252 sibpairs for linkage analysis.

Association was evaluated by quantitative transmission disequilibrium testing for both individual polymorphisms and haplotypes using the QTDT program (36). The transmission disequilibrium test was first developed for dichotomous traits in which alleles transmitted and not transmitted from the parents to affected offspring are compared to determine whether one allele is associated with the disease in question (37). It has the desired property of not giving spurious significant results attributable to population stratification because both case and control alleles come from the same parents. The transmission disequilibrium test was later extended to quantitative traits (38). Abecasis, Cardon, and Cookson (36) developed a general approach for scoring allelic transmission that accommodates families of any size and uses all available genotypic information. Family data allow the construction of an expected genotype for every nonfounder, and orthogonal deviates from this expectation are a measure of allelic transmission. The QTDT program implements this general transmission disequilibrium testing using the orthogonal model of Abecasis, Cardon, and Cookson (39). Age, sex, and BMI were specified as covariates. Environmental variance, polygenic variance, and additive major locus were specified in the variance model.

RESULTS

The clinical characteristics of the 291 subjects (112 men and 179 women) who had quantitative assessment of insulin resistance are shown in Table 2. This is an adult group of Mexican Americans of mean age 35.3 years. On average, these individuals are overweight. This may account for the degree of insulin resistance observed; however, it is known that Mexican Americans have a predisposition to visceral adiposity, hyperinsulinemia, and insulin resistance (40,41). The mean HOMA level suggests that these people are on average three to four times more insulin resistant than normal. The men had statistically significantly higher weight (*P* < 0.00001) and fasting glucose (*P* = 0.005) levels, while the women had significantly lower GINF (*P* = 0.0001) but not *M* values. These differences remained significant among the 284 subjects who were clamped and haplotyped.

Of the several indexes of insulin sensitivity, linkage with *LPL* haplotypes was demonstrated only for the direct quantification represented by GINF (*P* = 0.034). The *M* value, a clamp-derived index equal to GINF divided by body weight, was not significantly linked to *LPL* haplotypes (*P* = 0.32). All other measures (fasting glucose, fasting insulin, and HOMA) were not significant (*P* = 0.82, 0.44, and 0.34, respectively).

Association was evaluated by quantitative transmission disequilibrium testing. No haplotype was significantly associated with fasting glucose, fasting insulin, or HOMA, but both haplotypes 1 and 4 were significantly associated with GINF (haplotype 1, *P* = 0.031; haplotype 4, *P* = 0.007) and the *M* value (haplotype 1, *P* = 0.031; haplotype 4, *P* =

0.005). To characterize the nature of the associations of haplotypes 1 and 4 with insulin resistance, we determined the mean levels of insulin sensitivity in carriers of these haplotypes (Table 3 and Fig. 1). We observed that haplotype 1 is associated with the most favorable mean insulin sensitivity, while carriers of haplotype 4 had the lowest insulin sensitivity (i.e., the greatest insulin resistance). For fasting insulin, HOMA, GINF, and *M*, mean insulin sensitivity progressively deteriorated, going from haplotype 1 homozygotes to haplotype 1 heterozygotes to individuals without haplotype 1. Conversely, haplotype 4 heterozygotes were more insulin resistant than those without haplotype 4 (no haplotype 4 homozygotes were observed among the clamped subjects). Figure 2 further explores these associations by independently examining the effects of haplotypes 1 and 4 on insulin sensitivity. Exclusion of subjects with haplotype 4 from haplotype 1 heterozygotes and those without haplotype 1 did not affect the trend of benefit on insulin sensitivity seen with increasing numbers of haplotype 1. Similarly, excluding haplotype 1 carriers from those without and with haplotype 4 did not affect the trend of lower insulin sensitivity in the latter subjects; in fact, the subjects without haplotype 1 who were carriers of haplotype 4 had the lowest insulin sensitivity (most insulin resistance) compared with the other haplogenotype groups. Similar trends were observed with *M* value (data not shown).

DISCUSSION

LPL haplotypes showed both linkage and association with insulin sensitivity in this study of Mexican Americans ascertained via a parent with CAD. The strength of this investigation is that we examined a population at high risk for the insulin resistance syndrome on clinical genetic epidemiologic grounds, that we directly quantified insulin sensitivity by the euglycemic clamp study, and that we

TABLE 3
LPL haplotype means for indexes of insulin sensitivity

Haplotype carriers	Fasting glucose (mg/dl)	Fasting insulin (μIU/ml)	HOMA	GINF (mg/min)	<i>M</i> (mg · kg ⁻¹ · min ⁻¹)
1 (<i>n</i> = 239)	93.8	14.0	3.0	383.0*	5.3*
2 (<i>n</i> = 88)	95.2	14.6	3.1	365.9	4.9
3 (<i>n</i> = 56)	94.9	14.5	3.1	345.1	4.7
4 (<i>n</i> = 40)	93.3	15.5	3.2	344.3*	4.6*

*Significant association of phenotype with haplotype (see text).




FIG. 1. Effect of *LPL* 3' end haplotypes on indexes of insulin sensitivity. Each point represents the mean trait value for the haplogenotype indicated at the bottom. The thick line in the center of each graph represents the mean for the entire haplotyped and clamped population. Vertical lines represent SE.

combined this with the power of a haplotype-based analysis. The results suggest the presence of a common *LPL* haplotype in this population that protects against insulin resistance and a common haplotype that predisposes to

insulin resistance. Of interest, our prior work indicated that these same *LPL* haplotypes appear to protect and predispose, respectively, to clinical CAD (14).

The clustering of insulin resistance, hypertension, central obesity, and dyslipidemia in the metabolic syndrome is receiving much attention as a risk factor for cardiovascular disease. The central component of this syndrome, insulin resistance, has been found to increase cardiovascular risk. In the San Antonio Heart Study, insulin resistance, estimated by HOMA, was an independent predictor of incident cardiovascular events over 8 years of follow-up (4). In the Helsinki Policemen Study, 970 men free of diabetes or CHD at baseline were followed for 22 years; those with the highest levels of insulin resistance, as estimated by insulin area under the curve during oral glucose tolerance testing, had the highest rates of CHD events and death (3).

Our group is studying the *LPL* gene as a candidate gene for the insulin resistance syndrome. *LPL* hydrolyzes triglycerides carried in chylomicrons and VLDLs, the rate-limiting step in delivery of FFAs to muscle and adipose tissue. By controlling the delivery of FFA to muscle, *LPL* may affect insulin sensitivity by influencing levels of intramyocellular lipid, which correlate with muscle insulin resistance (42). In fact, transgenic mice with muscle-specific *LPL* overexpression exhibit whole-body and muscle insulin resistance (43). Conversely, in humans, a positive correlation between GINF and skeletal muscle *LPL* activity has been observed (44). Also, *LPL* may influence insulin resistance by affecting FFA delivery to visceral adipose tissue, which is increasingly viewed as an endocrine organ capable of secreting mediators of insulin resistance (45). *LPL* action also regulates the plasma triglyceride concentration, an important atherosclerosis risk factor (46). *LPL* activity indirectly raises HDL cholesterol levels because *LPL*-mediated hydrolysis of VLDL provides surface components that merge with HDL3 to form HDL2 particles (47). *LPL*-mediated delivery of FFA and lipoprotein remnants to vessel wall macrophages plays a role in foam cell formation, an early event in the development of atherosclerotic plaque (15). This atherogenic role of *LPL* is supported by studies wherein macrophages from *LPL* knockout mice prevented atherosclerosis when transplanted into irradiated atherosclerosis-prone LDL receptor knockout mice (48). Thus, functional variation in *LPL* may impact both insulin resistance and atherosclerosis.

LPL undergoes complex, tissue-specific regulation; for example, in the fed state, adipose *LPL* activity is increased and muscle *LPL* activity depressed, whereas the reverse is true in the fasting state (49). In insulin resistance/diabetes, macrophage *LPL* activity is increased and adipose *LPL* is decreased, with both alterations possibly contributing to atherosclerosis (15). The *LPL* haplotypes we have studied may contain variants that alter disease risk by affecting tissue-specific regulation of *LPL* activity. For example, one possibility is that haplotype 4 is associated with increased activity of *LPL* in muscle (promoting insulin resistance) and in macrophages (predisposing to atherosclerosis).

Most studies that have reported association of the *LPL* gene with insulin resistance used only surrogate measurements of insulin resistance, including fasting glucose




FIG. 2. Independent effects of haplotype 1 and haplotype 4 on insulin sensitivity. *Left:* Haplotype 1 genotypes with haplotype 4 carriers removed. *Right:* Haplotype 4 genotypes with haplotype 1 carriers removed. Each point represents the mean GINF value for each haplogenotype group. Vertical lines represent SE.

(16,17), fasting insulin (7,18–20), and insulin area under the curve during oral glucose tolerance testing (21). One study evaluated the steady-state plasma glucose during the insulin suppression test (8). In addition, all except one (20) of these studies only examined the association of the intronic restriction fragment–length polymorphisms *PvuII* and *HindIII*. Thus, current evidence that variation in *LPL* plays a role in insulin sensitivity has been indirect. Assessment of GINF during the hyperinsulinemic-euglycemic clamp study is widely regarded as the most direct physiologic measurement of insulin sensitivity (25). An analysis of indexes of insulin sensitivity in the Insulin Resistance Atherosclerosis Family Study showed that direct physiologic measurements of insulin sensitivity have a higher heritability than measures based on fasting values (such as HOMA) (50). Thus, use of physiologic indexes rather than simple fasting indexes should provide more power to discover genes that contribute to insulin sensitivity. Our study is the first that has used insulin sensitivity assessed by the euglycemic clamp as the phenotype in an association study with *LPL*. Consistent with the described higher heritability of physiologic indexes over fasting indexes, we showed a statistically significant association of *LPL* with GINF and *M* value but not with fasting glucose, fasting insulin, or HOMA. In addition, this study contains one of the largest family cohorts in the literature that have undergone the euglycemic clamp. We thus provide here statistical genetic evidence that *LPL* is an insulin resistance gene by demonstration of both linkage and association of *LPL* haplotypes with a direct quantitative measurement of insulin resistance in Mexican-American families ascertained via CAD. Whether these *LPL* haplotypes have the same relationship with insulin resistance in Mexican Americans without a family history of CAD or in other ethnic groups is unknown.

Two *LPL* haplotypes were associated with variation in GINF. These haplotypes had opposite effects on insulin sensitivity. Haplotype 1, the most common haplotype, was associated with improved insulin sensitivity. As the number of chromosomes in an individual with haplotype 1

decreased (from two, to one, to none), insulin sensitivity by GINF, as well as HOMA and fasting insulin, decreased progressively. Furthermore, haplotype 4 carriers had the lowest insulin sensitivity, i.e., they were the most insulin resistant. The direction of these associations persisted when the haplotypes were considered separately. The available data indicate that there is an insulin-sensitizing functional variant on haplotype 1 chromosomes and a variant on haplotype 4–bearing chromosomes that promotes insulin resistance. Current data does not allow us to distinguish whether the actual nucleotide locus responsible is the same for both haplotypes or whether such variation is at different locations in the gene. In terms of the relation to cardiovascular risk associated with the metabolic syndrome, our previous work has shown that haplotype 1 is associated with protection against CAD and that haplotype 4 may be associated with increased risk of CAD (14).

The benefit of a haplotype-based analysis is that it captures all of the variation across a region, which should improve the ability to detect an association. To our knowledge, we are the first to apply the haplotype approach to the study of *LPL* as a gene influencing insulin sensitivity. All prior published studies reporting association of the *LPL* gene with insulin resistance used only single variants, usually *HindIII* or *PvuII* (7,8,16–21). In some cases, the results are in conflict; studies have reported the T allele of *HindIII* associated with insulin resistance (7), others report the G allele associated with insulin resistance (8,21), and others show no association of *HindIII* with insulin resistance (16). This demonstrates a limitation of the common approach of examining one or two polymorphisms per candidate gene in an association study. By identifying whole chromosomal regions, haplotypes should have improved power and reproducibility in elucidation of disease-gene associations.

Multiple testing is an issue that applies to all genetic studies in which multiple genetic variants are tested for association against multiple traits. In such studies, including ours, adjusting for multiple comparisons by such

methods as Bonferroni corrections are typically not utilized because they result in a significance level that is too stringent, particularly for detection of associations of moderate genetic effects. The principal reason we did not adjust for multiple testing is that our goal was to test the prior hypothesis that *LPL* haplotypes are associated with the most direct measure of insulin sensitivity, that defined by the euglycemic clamp. Upon finding significant association of *LPL* haplotypes with GINF, we then explored the associations with the other indexes of insulin sensitivity. The consistency of the trends in measures of insulin sensitivity in relation to the *LPL* haplotypes (Fig. 1) supports our association results.

In the study herein, a haplotype-based approach successfully identified linkage and association of variation in the *LPL* gene with a direct physiologic measurement of insulin sensitivity in Mexican Americans, providing strong evidence that *LPL* is an insulin resistance gene. Given prior work demonstrating association of single variants with atherosclerosis, dyslipidemia, obesity, and hypertension, the haplotypes described here should be used in future studies exploring the association of the *LPL* gene with components of the insulin resistance syndrome, especially in the Mexican-American population.

ACKNOWLEDGMENTS

The MACAD project is supported in part by National Institutes of Health Program Project Grants HL-60030 and HL-28481. Further support came from the Cedars-Sinai Board of Governors' Chair in Medical Genetics (J.I.R.) and Cedars-Sinai General Clinical Research Center grant RR000425. M.O.G. was supported by National Research Service Award Training Grant 5 T32 GM08243-16.

We thank all the study participants and referring physicians. We also thank Dr. Jerrold Olefsky for helpful discussions.

REFERENCES

- Motulsky AG, Brunzell JD: Genetics of coronary atherosclerosis. In *The Genetic Basis of Common Diseases*, 2nd ed. King RA, Rotter JJ, Motulsky AG, Eds. New York, Oxford University Press, 2002, p. 105-126
- Park YW, Zhu S, Palaniappan L, Heshka S, Carnethon MR, Heymsfield SB: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988-1994. *Arch Intern Med* 163:427-436, 2003
- Pyorala M, Miettinen H, Laakso M, Pyorala K: Hyperinsulinemia predicts coronary heart disease risk in healthy middle-aged men: the 22-year follow-up results of the Helsinki Policemen Study. *Circulation* 98:398-404, 1998
- Hanley AJ, Williams K, Stern MP, Haffner SM: Homeostasis model assessment of insulin resistance in relation to the incidence of cardiovascular disease: the San Antonio Heart Study. *Diabetes Care* 25:1177-1184, 2002
- Allayee H, de Bruin TW, Michelle Dominguez K, Cheng LS, Ipp E, Cantor RM, Krass KL, Keulen ET, Aouizerat BE, Lusia AJ, Rotter JJ: Genome scan for blood pressure in Dutch dyslipidemic families reveals linkage to a locus on chromosome 4p. *Hypertension* 38:773-778, 2001
- Wu DA, Bu X, Warden CH, Shen DD, Jeng CY, Sheu WH, Katsuya T, Dzau VJ, Reaven GM, Lusia AJ, Rotter JJ, Chen YD: Quantitative trait locus mapping of human blood pressure to a genetic region at or near the lipoprotein lipase gene locus on chromosome 8p22. *J Clin Invest* 97:2111-2118, 1996
- Ahn YI, Ferrell RE, Hamman RF, Kamboh MI: Association of lipoprotein lipase gene variation with the physiological components of the insulin-resistance syndrome in the population of the San Luis Valley, Colorado. *Diabetes Care* 16:1502-1506, 1993
- Lee WJ, Sheu WH, Jeng CY, Young MS, Chen YT: Associations between lipoprotein lipase gene polymorphisms and insulin resistance in coronary heart disease. *Chung-Hua I Hsueh Tsa Chih [Chinese Medical Journal]* 63:563-572, 2000
- Holmer SR, Hengstenberg C, Mayer B, Döring A, Löwel H, Engel S, Hense HW, Wolf M, Klein G, Riegger GA, Schunkert H: Lipoprotein lipase gene polymorphism, cholesterol subfractions and myocardial infarction in large samples of the general population. *Cardiovasc Res* 47:806-812, 2000
- Heizmann C, Kirchgessner T, Kwiterovich PO, Ladas JA, Derby C, Antonarakis SE, Lusia AJ: DNA polymorphism haplotypes of the human lipoprotein lipase gene: possible association with high density lipoprotein levels. *Hum Genet* 86:578-584, 1991
- Jemaa R, Tuzet S, Portos C, Betoulle D, Apfelbaum M, Fumeron F: Lipoprotein lipase gene polymorphisms: associations with hypertriglyceridemia and body mass index in obese people. *Int J Obes Relat Metab Disord* 19:270-274, 1995
- Humphries SE, Nicaud V, Margalef J, Tiret L, Talmud PJ: Lipoprotein lipase gene variation is associated with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglycerides: the European Atherosclerosis Research Study (EARS). *Arterioscler Thromb Vasc Biol* 18:526-534, 1998
- Mattu RK, Needham EW, Morgan R, Rees A, Hackshaw AK, Stocks J, Elwood PC, Galton DJ: DNA variants at the *LPL* gene locus associate with angiographically defined severity of atherosclerosis and serum lipoprotein levels in a Welsh population. *Arterioscler Thromb Vasc Biol* 14:1090-1097, 1994
- Goodarzi MO, Guo X, Taylor KD, Quiñones MJ, Samayoa C, Yang H, Saad MF, Palotie A, Krauss RM, Hsueh WA, Rotter JJ: Determination and use of haplotypes: ethnic comparison and association of the lipoprotein lipase gene and coronary artery disease in Mexican-Americans. *Genet Med* 5:322-327, 2003
- Mead JR, Ramji DP: The pivotal role of lipoprotein lipase in atherosclerosis. *Cardiovasc Res* 55:261-269, 2002
- Nicklas BJ, Ferrell RE, Rogus EM, Berman DM, Ryan AS, Dennis KE, Goldberg AP: Lipoprotein lipase gene variation is associated with adipose tissue lipoprotein lipase activity, and lipoprotein lipid and glucose concentrations in overweight postmenopausal women. *Hum Genet* 106:420-424, 2000
- Proenza AM, Poissonnet CM, Ozata M, Ozen S, Guran S, Palou A, Strosberg AD: Association of sets of alleles of genes encoding beta3-adrenoreceptor, uncoupling protein 1 and lipoprotein lipase with increased risk of metabolic complications in obesity. *Int J Obes Relat Metab Disord* 24:93-100, 2000
- Cole SA, Aston CE, Hamman RF, Ferrell RE: Association of a PvuII RFLP at the lipoprotein lipase locus with fasting insulin levels in Hispanic men. *Genet Epidemiol* 10:177-188, 1993
- Ahn YI, Kamboh MI, Hamman RF, Cole SA, Ferrell RE: Two DNA polymorphisms in the lipoprotein lipase gene and their associations with factors related to cardiovascular disease. *J Lipid Res* 34:421-428, 1993
- Samuels ME, Forbey KC, Reid JE, Abkevich V, Bulka K, Wardell BR, Bowen BR, Hopkins PN, Hunt SC, Ballinger DG, Skolnick MH, Wagner S: Identification of a common variant in the lipoprotein lipase gene in a large Utah kindred ascertained for coronary heart disease: the -93G/D9N variant predisposes to low HDL-C/high triglycerides. *Clin Genet* 59:88-98, 2001
- Ukkola O, Garenc C, Perusse L, Bergeron J, Despres JP, Rao DC, Bouchard C: Genetic variation at the lipoprotein lipase locus and plasma lipoprotein and insulin levels in the Quebec Family Study. *Atherosclerosis* 158:199-206, 2001
- Daly MJ, Rioux JD, Schaffner SF, Hudson TJ, Lander ES: High-resolution haplotype structure in the human genome. *Nat Genet* 29:229-232, 2001
- Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D: The structure of haplotype blocks in the human genome. *Science* 296:2225-2229, 2002
- Templeton AR: Cladistic approaches to identifying determinants of variability in multifactorial phenotypes and the evolutionary significance of variation in the human genome. *Ciba Found Symp* 197:259-277, 1996
- DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. *Am J Physiol* 237:E214-E223, 1979
- Nickerson DA, Taylor SL, Weiss KM, Clark AG, Hutchinson RG, Stengård J, Salomaa V, Vartiainen E, Boerwinkle E, Sing CF: DNA sequence diversity in a 9.7-kb region of the human lipoprotein lipase gene. *Nat Genet* 19:233-240, 1998
- Livak KJ: Allelic discrimination using fluorogenic probes and the 5' nuclease assay. *Genet Anal* 14:143-149, 1999

28. O'Connell JR, Weeks DE: PedCheck: a program for identification of genotype incompatibilities in linkage analysis. *Am J Hum Genet* 63:259–266, 1998
29. Lewontin RC: The interaction of selection and linkage. I. General considerations; heterotic models. *Genetics* 49:49–67, 1964
30. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. *Diabetologia* 28:412–419, 1985
31. Kolterman OG, Insel J, Saekow M, Olefsky JM: Mechanisms of insulin resistance in human obesity: evidence for receptor and postreceptor defects. *J Clin Invest* 65:1272–1284, 1980
32. Sobel E, Lange K: Descent graphs in pedigree analysis: applications to haplotyping, location scores, and marker-sharing statistics. *Am J Hum Genet* 58:1323–1337, 1996
33. Haseman JK, Elston RC: The investigation of linkage between a quantitative trait and a marker locus. *Behav Genet* 2:3–19, 1972
34. SAGE: *Statistical Analysis for Genetic Epidemiology* [computer program]. Release 4.2. Cork, Ireland, Statistical Solutions, 2002
35. Elston RC, Buxbaum S, Jacobs KB, Olson JM: Haseman and Elston revisited. *Genet Epidemiol* 19:1–17, 2000
36. Abecasis GR, Cardon LR, Cookson WO: A general test of association for quantitative traits in nuclear families. *Am J Hum Genet* 66:279–292, 2000
37. Spielman RS, McGinnis RE, Ewens WJ: Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). *Am J Hum Genet* 52:506–516, 1993
38. Allison DB: Transmission-disequilibrium tests for quantitative traits. *Am J Hum Genet* 60:676–690, 1997
39. Abecasis GR, Cookson WO, Cardon LR: Pedigree tests of transmission disequilibrium. *Eur J Hum Genet* 8:545–551, 2000
40. Okosun IS, Liao Y, Rotimi CN, Prewitt TE, Cooper RS: Abdominal adiposity and clustering of multiple metabolic syndrome in white, black and Hispanic Americans. *Ann Epidemiol* 10:263–270, 2000
41. Haffner SM, Stern MP, Hazuda HP, Pugh J, Patterson JK, Malina R: Upper body and centralized adiposity in Mexican Americans and non-Hispanic whites: relationship to body mass index and other behavioral and demographic variables. *Int J Obes* 10:493–502, 1986
42. Boden G, Lebed B, Schatz M, Homko C, Lemieux S: Effects of acute changes of plasma free fatty acids on intramyocellular fat content and insulin resistance in healthy subjects. *Diabetes* 50:1612–1617, 2001
43. Pulawa LK, Eckel RH: Overexpression of muscle lipoprotein lipase and insulin sensitivity. *Curr Opin Clin Nutr Metab Care* 5:569–574, 2002
44. Yost TJ, Froyd KK, Jensen DR, Eckel RH: Change in skeletal muscle lipoprotein lipase activity in response to insulin/glucose in non-insulin-dependent diabetes mellitus. *Metabolism* 44:786–790, 1995
45. Guerre-Millo M: Adipose tissue hormones. *J Endocrinol Invest* 25:855–861, 2002
46. Malloy MJ, Kane JP: A risk factor for atherosclerosis: triglyceride-rich lipoproteins. *Adv Intern Med* 47:111–136, 2001
47. Eisenberg S: High density lipoprotein metabolism. *J Lipid Res* 25:1017–1058, 1984
48. Babaev VR, Patel MB, Semenkovich CF, Fazio S, Linton MF: Macrophage lipoprotein lipase promotes foam cell formation and atherosclerosis in low density lipoprotein receptor-deficient mice. *J Biol Chem* 275:26293–26299, 2000
49. Preiss-Landl K, Zimmermann R, Hammerle G, Zechner R: Lipoprotein lipase: the regulation of tissue specific expression and its role in lipid and energy metabolism. *Curr Opin Lipidol* 13:471–481, 2002
50. Bergman RN, Zaccaro DJ, Watanabe RM, Haffner SM, Saad MF, Norris JM, Wagenknecht LE, Hokanson JE, Rotter JI, Rich SS: Minimal model-based insulin sensitivity has greater heritability and distinct genetic basis than than homeostasis model assessment or fasting insulin. *Diabetes* 52:2168–2174, 2003